Seres therapeutics announces discontinuation of enrollment in ser-401 study in metastatic melanoma

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) announced today that the company, in collaboration with study partners, the parker institute for cancer immunotherapy (pici) and the university of texas md anderson cancer center, has voluntarily discontinued further enrollment in the melanoma checkpoint and gut microbiome alteration with microbiome intervention (mcgraw) study evaluating the safety and drug activity of ser-401 or fecal microbiota transplant (fmt) in comb
MCRB Ratings Summary
MCRB Quant Ranking